Moderna shares dive about 18% after reported leak of cancer-vaccine data ahead of presentation

Moderna’s shares fell sharply on October 22 after market reports said results from a cancer-vaccine effort with Merck circulated ahead of a scheduled scientific presentation. According to the report published by Yahoo Finance, the stock dropped roughly 18% as investors reacted to the prospect that the timing and handling of clinical data may have deviated from standard disclosure expectations.

The article tied the selloff to the circulation of cancer-vaccine information before Moderna had an opportunity to present the data publicly at the planned event. The centerpiece of the market reaction was not a revised forecast from the company, but rather how quickly the reported information reached investors relative to the conference schedule.

Merck was named in the report in connection with the cancer-vaccine work. While the Yahoo Finance account did not spell out what specific trial endpoint, patient population, or statistical result had been shared early, it indicated that the leaked or pre-circulated information involved data that Moderna planned to present.

In the biotech sector, conference presentations often serve as major milestones because they can crystallize the market’s view of whether a therapy is working and how large the potential benefit may be. When information reaches the market ahead of the planned forum, investors may reprice the stock immediately based on partial details, even before the company has a chance to provide the full context, methodology, and full dataset.

Moderna, like other mRNA-focused developers, has built much of its investor narrative around the progress and credibility of clinical programs. For these companies, trial data timing is especially sensitive because market expectations can swing quickly once performance indicates are interpreted, discussed, or publicized, whether through a formal release or informal circulation.

The reported incident also highlights a recurring challenge in drug development: ensuring that trial data, collaborations, and supporting materials are protected until they can be disclosed in a controlled manner. Even when the underlying science is later validated, early leaks can complicate trading and can increase scrutiny around corporate governance and compliance processes.

What Moderna itself did, if anything, in response to the report was not detailed in the Yahoo Finance post. The article also did not provide a breakdown of what Moderna confirmed publicly, whether it disputed the accuracy of the circulated information, or whether any regulatory, internal, or partnership review was initiated.

Investors will likely watch for follow-up clarity, including whether Moderna addresses the timing and provenance of the information, and whether the company’s planned conference presentation proceeds as scheduled with the full and final dataset. Any later corporate communication, including adjustments to disclosure timelines or additional context around the data, could affect how investors interpret the initial market reaction.